GB2598494B - A subunit vaccine for treatment or prevention of a respiratory tract infection - Google Patents

A subunit vaccine for treatment or prevention of a respiratory tract infection Download PDF

Info

Publication number
GB2598494B
GB2598494B GB2114836.6A GB202114836A GB2598494B GB 2598494 B GB2598494 B GB 2598494B GB 202114836 A GB202114836 A GB 202114836A GB 2598494 B GB2598494 B GB 2598494B
Authority
GB
United Kingdom
Prior art keywords
prevention
treatment
respiratory tract
tract infection
subunit vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
GB2114836.6A
Other languages
English (en)
Other versions
GB2598494A (en
GB202114836D0 (en
Inventor
PERUGI Fabien
Schwamborn Klaus
Schuler Wolfgang
Lundberg Urban
Meinke Andreas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Valneva SE
Original Assignee
Valneva SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valneva SE filed Critical Valneva SE
Publication of GB202114836D0 publication Critical patent/GB202114836D0/en
Publication of GB2598494A publication Critical patent/GB2598494A/en
Application granted granted Critical
Publication of GB2598494B publication Critical patent/GB2598494B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
GB2114836.6A 2019-05-20 2020-05-19 A subunit vaccine for treatment or prevention of a respiratory tract infection Active GB2598494B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19175413 2019-05-20
EP17054134 2019-05-20
PCT/EP2020/063973 WO2020234300A1 (en) 2019-05-20 2020-05-19 A subunit vaccine for treatment or prevention of a respiratory tract infection

Publications (3)

Publication Number Publication Date
GB202114836D0 GB202114836D0 (en) 2021-12-01
GB2598494A GB2598494A (en) 2022-03-02
GB2598494B true GB2598494B (en) 2024-07-24

Family

ID=66685352

Family Applications (1)

Application Number Title Priority Date Filing Date
GB2114836.6A Active GB2598494B (en) 2019-05-20 2020-05-19 A subunit vaccine for treatment or prevention of a respiratory tract infection

Country Status (21)

Country Link
US (3) US12162907B2 (https=)
EP (1) EP3972639A1 (https=)
JP (1) JP2022533318A (https=)
KR (1) KR20220010478A (https=)
CN (1) CN114127101A (https=)
AU (1) AU2020277661A1 (https=)
BR (1) BR112021021637A2 (https=)
CA (1) CA3138064A1 (https=)
CL (1) CL2021002819A1 (https=)
CO (1) CO2021014694A2 (https=)
EC (1) ECSP21079178A (https=)
GB (1) GB2598494B (https=)
IL (1) IL287099A (https=)
MX (1) MX2021013111A (https=)
MY (1) MY208001A (https=)
PE (1) PE20220400A1 (https=)
PH (1) PH12021552736A1 (https=)
SA (1) SA521430813B1 (https=)
SG (1) SG11202110646PA (https=)
WO (1) WO2020234300A1 (https=)
ZA (1) ZA202106883B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8986704B2 (en) 2012-07-06 2015-03-24 Valneva Austria Gmbh Mutant fragments of OspA and methods and uses relating thereto
WO2018189372A1 (en) 2017-04-13 2018-10-18 Valneva Austria Gmbh Multivalent ospa polypeptides and methods and uses relating thereto
PH12021552736A1 (en) 2019-05-20 2022-07-11 Valneva Se A subunit vaccine for treatment or prevention of a respiratory tract infection
CN115698044A (zh) 2020-04-09 2023-02-03 瓦尔尼瓦奥地利有限责任公司 用于医学用途的包含三种OspA融合蛋白的组合物
CA3174666A1 (en) 2020-04-09 2021-10-14 Robert Schlegl Improved methods of producing a lipidated protein
NZ798475A (en) 2020-10-09 2026-03-27 Univ Texas Prefusion-stabilized hmpv f proteins
JP2023549815A (ja) 2020-11-13 2023-11-29 アイコサバックス， インコーポレイテッド メタニューモウイルスのためのタンパク質ベースのナノ粒子ワクチン
JP2024522385A (ja) * 2021-04-09 2024-06-19 ヴァルネヴァ エスイー ヒトメタニューモウイルスワクチン
EP4380960A4 (en) * 2021-08-05 2025-07-02 Univ California GLYCOMODIFIED FOLDON DOMAINS AND RELATED COMPOSITIONS AND METHODS
EP4448802A1 (en) * 2021-12-16 2024-10-23 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion hmpv fusion proteins
JP2026504862A (ja) 2023-01-18 2026-02-10 ファイザー・インク 呼吸器疾患に対するワクチン
EP4661905A2 (en) * 2023-02-06 2025-12-17 Cyanvac LLC Modified piv5 vaccine vectors: methods of making and uses
WO2025126071A1 (en) 2023-12-14 2025-06-19 Pfizer Inc. Rna molecules
WO2025201243A1 (zh) * 2024-03-25 2025-10-02 中国医学科学院医学生物学研究所 重组呼吸道合胞病毒融合前f蛋白突变体和其用途
WO2026018181A1 (en) 2024-07-17 2026-01-22 Pfizer Inc. Immunogenic compositions and uses thereof
CN119176858B (zh) * 2024-11-22 2026-01-09 北京华诺泰生物医药科技有限公司 一种重组人偏肺病毒融合前f蛋白纯化方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004096993A2 (en) * 2003-04-25 2004-11-11 Medimmune Vaccines, Inc. Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus
US20180008697A1 (en) * 2014-12-24 2018-01-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Recombinant metapneumovirus f proteins and their use
WO2019092002A1 (en) * 2017-11-07 2019-05-16 Valneva Se Pharmaceutical compositions for treatment or prevention of viral infections

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5547871A (en) 1993-01-25 1996-08-20 American Cyanamid Company Heterologous signal sequences for secretion of insect controlling proteins
ATE509102T1 (de) 1994-07-15 2011-05-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
AT408721B (de) 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
AT409085B (de) 2000-01-28 2002-05-27 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
AU2001281812B2 (en) 2000-06-08 2005-04-07 Valneva Austria Gmbh Immunostimulatory oligodeoxynucleotides
AT410173B (de) 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung
US20040170642A1 (en) 2000-08-17 2004-09-02 Jorg Fritiz Vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide of a derivative thereof
AT410635B (de) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
US8715922B2 (en) * 2001-01-19 2014-05-06 ViroNovative Virus causing respiratory tract illness in susceptible mammals
JP4188092B2 (ja) 2001-05-21 2008-11-26 インターツェル・アクチェンゲゼルシャフト 免疫促進性オリゴデオキシ核酸分子
JP2005519035A (ja) 2001-12-07 2005-06-30 インターツェル・アクチェンゲゼルシャフト 免疫促進性オリゴデオキシヌクレオチド
DE10221836A1 (de) * 2002-05-16 2003-12-04 Lohmann Animal Health Gmbh Attenuierung von Metapneumovirus
ATE485056T1 (de) 2003-03-24 2010-11-15 Intercell Ag Verbesserte impfstoffe
AU2010264686A1 (en) 2009-06-24 2012-01-19 Glaxosmithkline Biologicals S.A. Vaccine
US20120315270A1 (en) 2009-10-21 2012-12-13 The United States Of America, As Represented By The Rsv immunogens, antibodies and compositions thereof
CN102145167A (zh) * 2010-02-05 2011-08-10 重庆医科大学附属儿童医院 重组人类偏肺病毒疫苗
AU2011258165B2 (en) 2010-05-26 2016-11-17 Selecta Biosciences, Inc. Dose selection of adjuvanted synthetic nanocarriers
ES2647882T3 (es) 2011-12-06 2017-12-27 Valneva Austria Gmbh Compuestos de aluminio para su uso en productos terapéuticos y vacunas
MY171210A (en) * 2013-06-17 2019-10-02 Janssen Vaccines & Prevention Bv Stabilized soluble pre-fusion rsv f polypeptides
CL2013002829A1 (es) 2013-10-01 2014-04-04 Univ Pontificia Catolica Chile Formulacion inmunogenica que contiene bcg vivas recombinantes que expresan antigenos de metapneumovirus (hmpv) en una suspension que se prepara a partir de un liofilizado sin la necesidad de adjuvante; su uso farmaceutico; vacuna contra hmpv.
CA2996762A1 (en) * 2015-08-31 2017-03-09 Technovax, Inc. Human respiratory syncytial virus (hrsv) virus-like particles (vlps) based vaccine
TW201729835A (zh) 2015-10-22 2017-09-01 現代公司 呼吸道病毒疫苗
EP3474893A1 (en) 2016-06-27 2019-05-01 The U.S.A. as represented by the Secretary, Department of Health and Human Services Self-assembling insect ferritin nanoparticles for display of co-assembled trimeric antigens
PH12021552736A1 (en) 2019-05-20 2022-07-11 Valneva Se A subunit vaccine for treatment or prevention of a respiratory tract infection
JP2024522385A (ja) 2021-04-09 2024-06-19 ヴァルネヴァ エスイー ヒトメタニューモウイルスワクチン

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004096993A2 (en) * 2003-04-25 2004-11-11 Medimmune Vaccines, Inc. Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus
US20180008697A1 (en) * 2014-12-24 2018-01-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Recombinant metapneumovirus f proteins and their use
WO2019092002A1 (en) * 2017-11-07 2019-05-16 Valneva Se Pharmaceutical compositions for treatment or prevention of viral infections

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MICHAEL B. BATTLES ET AL: "Structure and immunogenicity of pre-fusion-stabilized human metapneumovirus F glycoprotein", NATURE COMMUNICATIONS, vol. 8, no. 1, 16 November 2017 (2017-11-16) *

Also Published As

Publication number Publication date
CL2021002819A1 (es) 2022-07-08
PH12021552736A1 (en) 2022-07-11
KR20220010478A (ko) 2022-01-25
SG11202110646PA (en) 2021-10-28
US20240067681A1 (en) 2024-02-29
MY208001A (en) 2025-04-03
IL287099A (en) 2021-12-01
JP2022533318A (ja) 2022-07-22
ZA202106883B (en) 2022-07-27
GB2598494A (en) 2022-03-02
AU2020277661A1 (en) 2021-10-21
US12162907B2 (en) 2024-12-10
CA3138064A1 (en) 2020-11-26
EP3972639A1 (en) 2022-03-30
PE20220400A1 (es) 2022-03-22
WO2020234300A1 (en) 2020-11-26
SA521430813B1 (ar) 2024-04-27
GB202114836D0 (en) 2021-12-01
ECSP21079178A (es) 2021-11-30
MX2021013111A (es) 2021-11-17
US20250171501A1 (en) 2025-05-29
US20220185847A1 (en) 2022-06-16
BR112021021637A2 (pt) 2021-12-21
CN114127101A (zh) 2022-03-01
US12162909B2 (en) 2024-12-10
CO2021014694A2 (es) 2022-01-17

Similar Documents

Publication Publication Date Title
IL287099A (en) Subunit vaccine for the treatment and prevention of inflammatory diseases of the respiratory system
EP3925551C0 (en) CATHETER MOUTH DESIGNS
IL262104A (en) A mouthpiece for cooling a patient's oral tissue during therapeutic treatment
HUE058250T2 (hu) Gyógyszer rhinovírus-fertõzés megelõzésére vagy kezelésére
PL3307293T3 (pl) Preparaty do leczenia zaburzeń jamy ustnej, gardła i dróg oddechowych
IL268127A (en) Preparations containing adrevan for oral or gastric administration and their use for treatment
IL321414A (en) Vaccines against respiratory diseases
IL272562B1 (en) Compounds or pharmaceutically acceptable salts thereof for the treatment of mycobacterial infection
ES3030145T8 (en) Sars-cov-2 subunit vaccine
HK40072167A (en) A subunit vaccine for treatment or prevention of a respiratory tract infection
PT3609493T (pt) Tratamento de uma infeção vaginal bacteriana
GB201912059D0 (en) Combaination therapy of a patient subgroup
GB202312455D0 (en) A vaccine for the treatment or prevention of Burkholderia species infection in a subject.
PL4153302T3 (pl) Leczenie wirusowych zakażeń dróg oddechowych
GB202015584D0 (en) Treatment for viral infection
IL284669A (en) Gel type pharmaceutical composition for treating/preventing an infection
IL310974A (en) Prevention of lower respiratory tract infection with NIRSEVIMAB
GB202110146D0 (en) Treatment of respiratory conditions
ZA201907779B (en) Fabric for preventing/treating upper respiratory tract infection
IL275152A (en) System for hypothermia treatment of a patient
GB202004452D0 (en) Respiratory treatment device
AU2018900409A0 (en) Treatment of respiratory infection (3)
GB202108866D0 (en) Medico-surgical devices
GB202108786D0 (en) Medico-surgical devices
GB202101484D0 (en) Medico-surgical devices